Clinical Trials Browser

Phase 1 × INDUSTRY × Taxes × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

681 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07488884 2026-03-23

ResQ108B-PANC

Phase 1 Not yet recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

470 enrolled

Tumor-Agnostic

Neoplasms

NCT05300048 2025-10-06

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Phase 1 Completed

34 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06182072 2025-10-01

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1 Recruiting

46 enrolled

Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1 Completed

446 enrolled 49 charts

Other solid neoplasm

Locally Advanced and Metastatic Solid Tumors

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03918278 2025-06-25

MK-0482-001

Phase 1 Completed

222 enrolled

Tumor-Agnostic

Neoplasms

NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1 Completed

35 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Phase 1 Completed

139 enrolled

Gastrointestinal

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT03505528 2019-11-13

Epi-PRIMED

Phase 1 Completed

8 enrolled

Breast

Breast Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

A Study of ASP3082 in Adults With Advanced Solid Tumors

ResQ108B-PANC

MK-4830-001

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

MK-0482-001

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Epi-PRIMED